Uriviga M 50 Tablet contains Tamsulosin 0.4mg + Mirabegron 50mg, a dual-action therapy for managing urinary disorders, including bladder outlet obstruction and overactive bladder. Tamsulosin relaxes the smooth muscles of the urinary tract to improve urine flow, while Mirabegron supports bladder muscle relaxation and reduces urgency, ensuring comprehensive symptom relief and patient comfort.
This combination is highly trusted by prescribers due to its consistent efficacy, tolerability, and patient-friendly dosing, generating steady demand. Patients experience better urinary function, reduced frequency, and improved adherence, making it a preferred choice in urology therapy.
For franchise partners, Uriviga M 50 Tablet is a high-demand urology product with strong market potential. Its proven therapeutic effectiveness and prescriber confidence make it a profitable addition to urology portfolios, helping partners expand their reach and increase business growth.
With its dual benefit of urinary relief and bladder health support, Uriviga M 50 Tablet provides sustainable sales opportunities, making it an excellent choice for partners targeting the urology and urinary care market.